Core Viewpoint - Aptose Biosciences Inc. shareholders are recommended to vote "FOR" the proposed arrangement with Hanmi Pharmaceutical Co. Ltd. to acquire all outstanding common shares not currently owned by Hanmi or its affiliates [1][8] Group 1: Arrangement and Continuance - Glass Lewis, an independent proxy advisory firm, has recommended that shareholders approve the arrangement with Hanmi [1] - The company is transitioning from being governed under the Canada Business Corporations Act to the Business Corporations Act (Alberta) [2] - The completion of the transaction is subject to customary closing conditions, including court approval and approval from the TSX [8] Group 2: Meeting Details - A special meeting of shareholders has been reconvened for March 31, 2026, at 11:00 a.m. (EST) to seek approval for the arrangement and continuance [4] - The meeting will be held virtually via live audio webcast [4] - Shareholders are encouraged to submit their proxies ahead of the voting deadline on March 27, 2026, at 11:00 a.m. (EST) [3][7] Group 3: Proxy Statement and Voting Assistance - Aptose has filed a definitive proxy statement with the SEC for the reconvened meeting, which has been mailed to all shareholders [5] - Shareholders who have questions or need voting assistance can contact Morrow Sodali (Canada) Ltd. [10]

Core Viewpoint - Aptose Biosciences Inc. has received a recommendation from Institutional Shareholder Services (ISS) for shareholders to vote "FOR" the special resolution to approve the acquisition arrangement with Hanmi Pharmaceutical Co. Ltd. [1][2] Transaction Details - The arrangement involves Hanmi and its subsidiary acquiring all outstanding common shares of Aptose not owned by them, with shareholders receiving C$2.41 in cash per share, representing a 28% premium over the 30-day volume-weighted average price (VWAP) of C$1.88 [3] - The transaction is subject to customary closing conditions, including court approval and approval from the Toronto Stock Exchange (TSX) [9] Meeting Information - A special meeting for shareholders to approve the arrangement and continuance has been reconvened for March 31, 2026, at 11:00 a.m. (EST), to be held virtually [4] - The proxy voting deadline is set for March 27, 2026, at 11:00 a.m. (Eastern time) [7] Shareholder Communication - Aptose has filed a definitive proxy statement with the SEC and mailed it to all shareholders, providing necessary voting materials [5] - Morrow Sodali (Canada) Ltd. has been retained to assist with shareholder communications and proxy solicitation [10] Company Overview - Aptose Biosciences Inc. is a clinical-stage biotechnology company focused on developing precision medicines for oncology, particularly in hematology [10]